Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 34,000 | |||
5 mg | 在庫あり | ¥ 72,000 | |||
10 mg | 在庫あり | ¥ 112,000 | |||
25 mg | 在庫あり | ¥ 180,500 | |||
50 mg | 在庫あり | ¥ 257,000 | |||
100 mg | 在庫あり | ¥ 340,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 79,500 |
説明 | TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy. |
ターゲット&IC50 | Cav 3.2 (a1H):92 nM, Cav 3.1 (a1G):89 nM |
In vivo | TTA-A2 (oral gavage; 10 mg/kg; once daily; 5 days) shows selective effect on recurrent thalamocortical network activity, it suppresses active wake and promotes slow-wave sleep in wild-type mice but not in mice lacking both Cav3.1 and Cav3.3[1].TTA-A2 (oral gavage;?3 mg/kg;?single dose) produces significant changes in sleep architecture in rats.?A reduction in active wake soon after dosing with a concurrent increase in delta sleep and decrease in REM sleep.?Additionally, these effects persists for up to 4 h post-dose in rats[2]. |
分子量 | 378.39 |
分子式 | C20H21F3N2O2 |
CAS No. | 953778-63-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (72.68 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TTA-A2 953778-63-7 Membrane transporter/Ion channel Metabolism Calcium Channel Pregnane X receptor neurological diseases T-type calcium channel Inhibitor Ca2+ channels Ca channels Electrocorticogram TTAA2 sleep disorders TTA-A-2 inhibit TTA A2 Epilepsy inhibitor